In conclusion, our study indicated that the PNPLA3 and SIRT5 polymorphisms, individually and in combination, might influence the severity of fibrosis in patients with MASLD. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.